BENGALURU, May 15 (Reuters): Drugmaker Granules India posted a 1.6 per cent fall in fourth-quarter revenue on Wednesday, hurt by a decline in paracetamol sales and price erosion.
The company's consolidated revenue fell year-on-year to 11.76 billion rupees (nearly $141 million) for the three months to March 31.
Granules, which focuses on making active pharmaceutical ingredients (API), holds 30 per cent of the global market for Paracetamol. It makes the drug's API as well as the finished dosage - the ready-for-consumption product.
Still, weak sales of the drug and price erosion due to heightened competition hurt its revenue.
Granules India posts Q4 revenue fall on weak paracetamol sales
FE Team | Published: May 15, 2024 22:12:02
Granules India posts Q4 revenue fall on weak paracetamol sales
Share if you like